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Summary
Background: The treatment of tuberculosis (TB) with category I regimen of the Revised National Tuberculosis Control
Programme (RNTCP) for patients with diabetes mellitus (DM) needs evaluation.
Objective: To assess the cure and relapse rates in 3 years, among the new smear-positive TB patients with Type-2 DM
(DMTB) treated with CAT-I regimen (2E3H3R3Z3/4R3H3) of RNTCP.
Methodology: TB suspects attending the diabetology units and the TB research centre (TRC) Chennai, were investigated.
Eligible DMTB cases were enrolled. Baseline estimation of cardiac, renal, liver function tests and glycosylated-HBA1c
were undertaken. All patients received 2E3H3R3Z3/4R3H3 under supervision at TRC. Clinical and sputum (smear and
culture) examinations and monitoring of diabetic status were undertaken every month up to 24 months, then once in 3
months up to 36 months.
Results: Of 100 patients admitted, 7 were excluded for various reasons from analysis. Of 93 patients, 87 (94%) had a
favourable response at the end of treatment. Pre and post treatment mean glycosylated-HBA1c were 9.7% and 8.4
%.(>7% poor control). During follow-up period, 6 died and one lost to follow-up. Of the remaining, four relapsed.
Conclusion: Category-I regimen, recommended for all the new smear-positive patients in the Indian TB programme, is
effective in the treatment of DMTB patients, despite poor control of diabetes.
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INTRODUCTION
Prevalence of Diabetes Mellitus (DM) is
increasing in epidemic proportions in Asian countries
and it is 8% in rural and 13% in urban population in
India.1,2 Pulmonary TB (PTB) has been reported to
be five to six times more common among diabetics,
compared to non-diabetics and causes a greater
mortality.3,4 Active tuberculosis intensifies Diabetes
Mellitus and vice versa; thus the two diseases constitute
a dreaded companion.5 Generally it is felt that TB
patients with Diabetes (DMTB) need longer duration
of treatment and they have been treated with regimens
of longer than 12 months duration, even though short-
course chemotherapeutic regimens (SCC) of 6-9
months have been proven to be effective both in
pulmonary and extra-pulmonary forms of TB.6-8.
In India, under Revised National TB
Control Programme (RNTCP) Category-I regimen
(CAT-I, 2E3H3R3Z3/4R3H3) an intermittent 6
months regimen  is recommended for all the new
smear positive patients.9  Hence it is proposed to
assess the cure and relapse rates during a period
of 3 years following treatment with  CAT-I
regimen in DMTB.
METHODS
Study design and objective
A prospective, observational cohort
study was undertaken to assess the adequacy
of CAT-I regimen in the new smear positive
DMTB patients.
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Collaborating institutions
The collaborating Institutions were the
Diabetology Units of Government Hospitals, Institute
of Thoracic Medicine, and Tuberculosis Research
Centre (TRC), Chennai. All diabetics patients
suspected to have tuberculosis attending these
hospitals were investigated.
Eligibility criteria
A patient was eligible for enrolment, if all
the following conditions were satisfied. Known Type-
2 diabetics, who were diagnosed as diabetics in the
outpatient departments of the hospitals, not insulin
dependant, with at least 2 positive sputum smears
for AFB, aged >30 years, has not had >1 month of
previous ATT, living in Chennai or its outskirts, was
willing to attend as required for 3 years, willing to
have medicaments administered under supervision
three times a week during the treatment period and
for blood tests and other investigations at periodic
intervals.
Exclusion criteria
Patients were not eligible for enrolment, if
they were too ill or in moribund condition or with
history suggestive of bleeding diathesis or fits or with
creatinine levels >2 mg/dl or with acetone in urine
or patients with end stage complications of DM such
as proliferative retinopathy or nephropathy.
Study patients
New sputum smear and culture positive
DMTB patients formed the study population.
Sample size
The sample size was calculated on the
following basis: The efficacy of a 6-month regimen
2H3R3E3Z3/4H2R2 investigated at TRC, among the
new sputum positive tuberculosis patients, without
associated diabetes mellitus was 89%.10 Anticipating
an efficacy of 83% for the current regimen
2H3R3E3Z3/4H3R3 among diabetic patients, with type-
1 error of 0.05, approximate sample size was
calculated to be 74. Allowing for a 20% drop-out,
for 3 years the sample size was 74+15 or 90 patients.
Assessments and investigations
The list of investigations and assessments
undertaken prior to start of treatment is given below:
A full plate P.A. view of X-ray chest was taken and
the radiological extent of the lesion was classified as
per the number of zones or lobes involved and
presence or absence of cavity. Four sputum
specimens were examined (2 spot and 2 home) by
smear and culture for Mycobacterium Tuberculosis.
If less than two smears were positive two more
additional smears were examined. Mantoux test with
1 tuberculin (RT 23 with Tween 80) on the flexor
aspect of the left forearm; the greatest diameter of
palpable induration was measured and presence or
absence of erythema was marked after 72 hours.
Urine examination for albumin, sugar, acetone,
deposits, bile pigments, acetyl INH and Rifampicin
was undertaken. Blood was examined for routine
liver function tests, renal function tests, fasting blood
sugar, glycosylated haemoglobin and lipid profile. HIV
screening was undertaken for all patients. Diabetic
status was assessed based on glycosylated
haemoglobin percentage; <7% was taken as normal
value and >7% was considered as abnormal value.
History of contact with pulmonary TB patients was
enquired. If present, the relationship to the patient
was recorded. Presence or absence of family history
of Diabetes Mellitus was also recorded. A detailed
examination of cardiovascular system including
condition of peripheral vessels and ECG was done
to ascertain cardiac status. Tests for sensitivity to
streptomycin, Isoniazid, Ethambutol and rifampicin
on two positive pre-treatment sputum cultures were
undertaken. A detailed neurological examination was
undertaken to assess the status particularly of
peripheral nerves and examination of respiratory
system, abdomen, skin, and joint involvement was
undertaken. Details of duration of diabetes, treatment
of diabetes, and family history of diabetes, including
treatment such as oral anti-diabetic drugs and or
insulin injection was obtained for all patients. A
detailed ophthalmic examination was carried out to
assess the status of retina. Any past events like
history of gangrene, bronchial asthma, convulsion
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or jaundice, bleeding disorders were obtained.
The list of investigations and assessment
during and in the follow-up period are listed in
Table-1.
Bacteriological procedures
Sputum smears were examined for AFB by
fluorescence microscopy. The specimens were
processed by modified Petroff’s method and cultured
on the Lowenstein Jenson medium. The sputum
smears were graded according to the number of
bacilli visualized per high power field (HPF) and all
positive cultures were subjected to identification tests
for Mycobacterium tuberculosis and to drug
susceptibility tests described elsewhere.11,12
Treatment regimen for tuberculosis
All patients were given a six-month SCC
(2H3R3Z3E3/4H3R3) regimen, consisting of 2-months
of isoniazid (H) plus Rifampicin (R) plus Ethambutol
(E) plus Pyrazinamide (Z) three times a week
followed by 4 months of isoniazid plus Rifampicin
three times a week. Every dose of treatment was given
under supervision. The dosages were as follows:
H=600mg, R=450mg, E=1200mg and Z=1500mg.
Defaulter action
If a patient fails to attend on a due date for
treatment, prompt retrieval actions were undertaken
by a health visitor/social worker/physician.
Management of diabetes
All patients were seen by a diabetologist at
TRC once a week and oral anti-diabetic drugs (ADT)
were adjusted based on fasting blood sugar levels.
Insulin injections were given only after completing
ATT.
Management of adverse reactions to ATT
If a patient made a spontaneous complaint,
attributable to ATT, was referred to a physician, who
recorded the complaints in detail and managed
appropriately.
Definitions used for primary treatment outcomes
Favourable response: If all six sputum cultures
were negative during the last 2-months of
chemotherapy or if one culture was positive during
the last 2-months with negative cultures subsequently
(without additional chemotherapy).
Clinical examination, recording of adherence to 
treatment and adverse reactions if reported 
Every month upto 24months, once every 3 
months upto 36months  
Smear and culture examination  of  three sputum 
specimens  
Two sputum specimens  
 
Every month upto 6 months 
Once every 3 months upto 36 months 
Estimation of Fasting blood sugar 
 
Glycosylated HBA1c 
Every month upto 24 months, then once every 3 
months upto 36 months  
Once every 3 months upto 36 months  
Examination by Diabetologist  Every month upto 24 months, Once every 3 
months upto 36 months 
Renal & liver function tests  0,6,12, 24, 36 months 
Chest radiograph 2,6,12,24 & 36 months 
Urine examination for acetone, sugar, albumin 
including deposits 
Every month upto 24 months, then once every 3 
months upto 36 months  
Cardiac, ophthalmological and neurological 
assessments 
 
0 and 6 months 
 
Table 1: Investigations and assessments during treatment and follow-up period
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Unfavourable response: When (a) two or more
cultures were positive in last two months of
treatment, including at least one in the last month,
with at least one culture growing 20 colonies or more,
or (b) persistent bacteriological positivity or
radiographic and/or clinical deterioration warranting
change of chemotherapy, or (c) death due to
tuberculosis during the treatment phase or (d) change
of treatment for adverse drug reactions.
Bacteriological relapse requiring treatment
Among patients with a favourable response,
relapse requiring treatment was defined as a total of
two or more cultures positive for M. Tuberculosis in
any two consecutive months during the follow-up
period, at least one with a growth of >20 colonies
with a positive smear, or persistent radiological
deterioration with a positive smear or clinical
deterioration during the follow-up period.
Data analysis
Intention-to-treat analysis and analysis of
adverse reactions were undertaken. The proportion
of patients who became sputum smear negative and
or culture negative at the end of intensive phase were
also analysed.
This study was done after getting the
approval from the Scientific Advisory Committee and
the Institutional Ethics Committee of TRC.
RESULTS
Patients’ enrolment
A total of 258 patients (January 1998-
January 2002) with Type-2 Diabetes Mellitus with
suspected tuberculosis were assessed and 87 did not
meet the inclusion criteria, 48 refused to participate
and 23 were not included for other reasons. The
remaining 100 patients were enrolled.
Patients in analysis
Intention to treat analysis included 98
patients, two however, refused treatment. Baseline
characteristics of patients and analysis of adverse
reactions were undertaken in all 100 patients
enrolled.
Baseline characteristics of study population
(Table 2)
The median age was 48 years (range 30-70
years), 72% were males and median weight was
51.5kg. Radiological involvement of >2 zones in
61%,  bilateral in 50%, lower lobe in 19%, middle
lobe in 45% and presence of cavity in 21%. Table 2
describes the initial smear and culture grading.
Ninety-six per cent of patients were infected with
organisms susceptible to S, H, R and E, 3% resistant
to INH and 1% to Rifampicin.
Profile of diabetic status
Duration of diabetes was <6 months in 50%
of patients (Table-2). Of them 51% were on oral
anti-diabetics (ADT), 18% on insulin and 20% on
both insulin and ADT. Median glycosylated HbA1c
(good control <7%) was 10.1% (range 6.9-14%).
The median fasting sugar was 238 (range 78-518)
mg per d/l. Initially, 13% had mild non-proliferative
retinopathy, maculopathy in 2%, ischemic heart
disease in 2%, macroalbuminuria in 5%, distal
peripheral sensory neuropathy in 15% and 64% did
not have any complications.
Drug regularity
The amount of scheduled anti-TB medication
received was >75% in 91, 60-65% in 3 and 2 had
completed 50-92% of intensive phase only, 2 patients
refused treatment after 5th and 6th doses and in two
treatment was changed for severe adverse reactions.
Smear conversion during treatment
Of 93 patients in analysis, conversion to
smear negativity occurred in 26 (28%) by the first,
57 (61%) by the second, 76 (82%) by the third and
88 (95%) by the 6th month. Conversion to culture
negativity occurred in 34 (37%) by the first, 82 (88%)
by the second, 90 (97%) by the 3rd and 4th but 89
(96%) by the sixth month.
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Profile of diabetes at the end of treatment and
follow-up
At the end of treatment the glycosylated
HBA1c was 8.4% and the median fasting blood sugar
was 184 (86-412) mg/dl. At the 30th month of follow-
up the median fasting blood sugar was 214 (78-515)
mg/dl.
Management of adverse reactions to Anti-
Tuberculosis Treatment (ATT)
Of 100 patients 89 did not have any
problems. Adverse reactions attributable to ATT
occurred in 11. Two developed severe toxicity to
Rifampicin and Pyrazinamide and both drugs were
terminated; one developed persistent vomiting with
fever, after two-weeks of treatment and the other
vasculitis (pruritic rashes with itching) after one-
month of treatment. Arthralgia occurred in three,
gastro-intestinal symptoms in six and these patients
responded to symptomatic management.
Treatment outcome
Intention to treat analysis and relapses in
the follow up period of 36 months from enrolment
to study (Fig.): Of 100 patients enrolled, intention-
to- treat analysis was done for 98 patients (two
refused treatment after 5 and 6 doses). Of 98, 92
(94%) had a favourable response and six patients
had unfavourable bacteriological response. Of six
who had unfavourable response, three patients with
initially drug sensitive organisms developed resistance
Characteristics   Per cent 
Sex  Males  72 
Age (yrs) Median   
Range 
48 
30-70 
Weight (Kg )  Median 
Range 
51.5 
32.6 - 74.7 
X-ray chest 
        Lung zones involved 
 
>2 Zones 
 
61 
       Lower lobe involvement         
       Middle lobe involvement 
       Cavity  
 19 
45 
21 
       Extent of the disease Bilateral 50 
Initial Smear grading 1+  
2+  
3+  
46 
43 
11 
Initial culture grading <1+ 
2+ 
3+  
13 
25 
62 
Sensitivity pattern  HRES sensitive   
Resistant to H 
Resistant to R   
96 
3 
1 
Duration of diabetes <6 months 
6months-2 years  
2 -5 years  
>5 years 
50 
20 
10 
20 
Family history of DM  41 
History of contact with TB  9 
 
Table 2: Baseline characteristics of study population (n=100)
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to isoniazid alone at the 5th month and remained smear
and culture positive at the end of treatment and 2
had change of treatment for severe adverse reactions.
One other patient with organisms initially resistant
to Rifampicin alone, remained smear and culture
positive at the end of treatment.
During 30 months of follow-up among 92
patients, 4 (4%) relapsed at the 11th, 12th, 13th and
30th months period; 6 died; 3 due to myocardial
infarction, 2 of cardiac failure and one committed
suicide.
Pre and post-treatment radiological assessments
(Table 4)
Post–treatment, cavity closure was observed
in 19 of 21 patients and 80% had fibrotic lesions.
Response related to initial sensitivity pattern
Of 100 patients, 96 had organisms
sensitive to Rifampicin, Isoniazid, Streptomycin
and Ethambutol. Of 3 patients with resistance to
Isoniazid, all had a favourable response. One
patient, with initial Rifampicin resistance failed to
treatment.
DISCUSSION
This study has shown that CAT-I regimen
(intermittent six-month regimen) of RNTCP was
adequate in Type-2 DMTB patients, as  the
treatment success was 94% and 4% relapsed in
30 months of  follow-up. The treatment outcomes
are comparable to that of non-diabetics. This
indicates that association of diabetes did not
influence the outcome of TB treatment. This is in
contrast to that reported earlier from Japan, where
despite treatment with chemotherapeutic
regimens of 9-12 months or more the relapse rates
in 30 month follow-up period was 10%.6 Our
finding is contrary to that reported earlier that DM
was a risk factor for relapses in TB patients and
thus can allay the concerns of diabetologists and
TB programme managers across the globe, as the
relapses were not higher among diabetic patients
compared to non-diabetics.6-8
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It is reported that strict glycaemic
equilibrium is essential for the success of ATT among
the DMTB patients.4 But in our series, despite poor
diabetic control, majority of our patients had
responded to ATT. Even though it is recommended
that smear positive DMTB patients should be treated
with insulin injections, as a policy, they were treated
only with oral anti-diabetic drugs during the period
of ATT. It is worth noting that this practice did not
result in therapeutic penalty.13
Although our patients were on both
Rifampicin and oral anti hypoglycemic drugs,
adverse reactions to ATT were not a major problem.
This finding highlights the suitability of this RNTCP
regimen to DMTB patients.
The low smear conversion rates (61%)
observed in this series, compared to the National
average of 80% is more likely to be due to the use of
the fluorescent auramine rhodamine stain, which is
known to be more sensitive than the Ziehl Neelsen
stain in sputum smear reading for acid fast bacilli.14,15
Patients (54%) with higher smear grading (2+ and
3+) initially were less likely to convert, compared to
patients (46%) with 1+ smear. Similar findings have
been reported earlier.16-18 Initially 87% of our patients
had higher culture grading. At the end of intensive
phase, culture conversion was 88% and smear
conversion was 61%. Culture conversion is a
surrogate marker of the sterilising activity of the
regimen.19 This is borne out of by the high proportion
of patients with a favourable response (94%) at the
end of treatment. These findings are similar to our
findings observed among PTB patients with or
without HIV infection20,21. These findings
demonstrate the competence of the RNTCP regimen
in the treatment of DMTB.
Majority of our patients (96%) were infected
with organisms, sensitive to RHES etc (first line
drugs). This probably reflects the drug susceptibility
profile, among diabetics attending the diabetic clinics
of two of the teaching hospitals of the city. Similar
findings have been reported by Singla et al.22 However
this is contrary to a report from an Indian tertiary
hospital, where only 51% of the DMTB patients were
infected with sensitive organisms.23 This is possibly
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due to the diverse spectrum of cases seen at tertiary
hospitals, as complicated cases were more likely to
throng specialized hospitals. Another important
finding is that all the 3 patients infected with
organisms, resistant to isoniazid responded well to
the CAT-I regimen, indicating the potency of the CAT-
I regimen in isoniazid resistant patients.
None of our patients had Multi-Drug
Resistance (MDR), similar to Singla’s series22 This
is contrary to earlier reports, where higher
proportions (26% from south India and Bellevue)
had MDR-TB among DMTB patients.23,24 Thus there
are conflicting reports about incidence of MDR-TB
among diabetics and more studies are needed in this
area.
In our series, even though the clinical profile
was similar to that of PTB, the radiological images
were atypical as 45% had middle lobe and 19% had
lower lobe involvement, similar to earlier reports.25-
28
 Six patients died due to cardiac problems unrelated
to tuberculosis. Higher mortality rates due to the
diabetic complications is well known.2-4
This study is not without limitations. The
glycosylated HBA1c was undertaken for all patients
enrolled initially but was done only for half of the
patients, in the follow up period, as the kit was not
available. Therefore, monitoring of the diabetic status
was done by estimation of fasting blood sugar.
To conclude, this cohort analysis has proved
that DMTB patients have similar clinical presentation
as PTB, but atypical radiological presentation, higher
bacillary load at the time of diagnosis as shown by
higher culture grading, a lower prevalence of anti-
tuberculous drug resistance and excellent outcome
to ATT. This study lends support to the current
practice of treating all the new sputum positive
patients with diabetes mellitus with CAT-I regimen
under RNTCP.
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